Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
890.68
-15.86 (-1.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Regeneron Announces Investor Conference Presentations
October 25, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Stock-Split Watch: Could These 2 Growth Stocks Be Next?
October 25, 2023
Neither company has discussed it, at least not yet.
Via
The Motley Fool
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
October 25, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END
Via
FinancialNewsMedia
$100 Invested In This Stock 20 Years Ago Would Be Worth $6,000 Today
October 19, 2023
Via
Benzinga
Price Over Earnings Overview: Regeneron Pharmaceuticals
October 17, 2023
Via
Benzinga
The Latest Analyst Ratings for Regeneron Pharmaceuticals
October 11, 2023
Via
Benzinga
Down 45%, Is Intellia a Buy?
October 10, 2023
Intellia's operating in the high-growth field of gene editing.
Via
The Motley Fool
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
October 22, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
October 21, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
October 21, 2023
The venerable pharmaceutical companies' shares have slumped this year.
Via
The Motley Fool
Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
October 20, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
P/E Ratio Insights for Regeneron Pharmaceuticals
October 06, 2023
Via
Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
October 04, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
October 18, 2023
Via
Benzinga
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
October 18, 2023
The company can begin a pivotal study of its treatment for cardiomyopathy.
Via
Investor's Business Daily
Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN
October 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
October 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Pharmaceuticals Unusual Options Activity
October 03, 2023
Via
Benzinga
Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) Deserves Consideration as a Quality Investment.
October 17, 2023
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN)
Via
Chartmill
Healthcare Portfolio Focus Stocks
October 16, 2023
The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields.
Via
Talk Markets
Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
October 16, 2023
Via
Benzinga
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
October 16, 2023
These two large-cap biopharma companies could have more room to run.
Via
The Motley Fool
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
October 15, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points
October 14, 2023
Broadcom and Arista lead five stocks sporting a flat base.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up
October 09, 2023
Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment.
Via
Talk Markets
Biotech Sector: On The Verge Of Triumph Or Turmoil?
October 06, 2023
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.
Via
Talk Markets
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
October 05, 2023
First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
This Market-Beating Stock Just Gave Investors More Reasons to Invest
October 05, 2023
There is a lot going the way of this biotech giant right now.
Via
The Motley Fool
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
October 05, 2023
This stock puts the "big" in big pharma after massive gains in recent years.
Via
The Motley Fool
MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer
October 03, 2023
MAIA Biotechnology, Inc. (AMEX: MAIA) announced that the U.S.
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.